Crispr Therapeutics shares tumble after significant earnings miss
Olivier Biebuyck, President, Fab Tech at ESAB Corp (NASDAQ:ESAB), sold 1,440 shares of the company’s common stock on July 31, 2025, at a price of $133.49, totaling $192,225. The transaction comes as ESAB, an $8.1 billion market cap industrial company, trades near its 52-week high of $135.97. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
On the same day, Biebuyck also exercised options to acquire 4,413 shares of ESAB Corp at a price of $46.94, amounting to $207,146. Following the exercise of these options, 2,973 shares were withheld by ESAB Corp to cover tax liabilities, valued at $135.68 per share, for a total of $403,376. With the company’s earnings report due on August 6, investors tracking insider movements can access comprehensive analysis through InvestingPro’s detailed research reports, which cover over 1,400 US stocks.
Following these transactions, Biebuyck directly owns 14,989 shares of ESAB Corp. The stock currently trades at a P/E ratio of 26x, with analysts maintaining price targets ranging from $122 to $150 per share.
In other recent news, ESAB Corporation has announced a definitive agreement to acquire EWM GmbH, a German-based manufacturer of heavy industrial welding equipment, for approximately €275 million. This acquisition is expected to significantly enhance ESAB’s presence in the German heavy fabrication market. The transaction is anticipated to close in the second half of 2025, pending regulatory approvals. In related developments, Loop Capital maintained its Hold rating on ESAB following the acquisition announcement, with a price target of $120.00, highlighting the strategic alignment with ESAB’s goal to expand higher-margin equipment sales globally.
Stifel has also been active in their analysis of ESAB, recently raising the stock’s price target to $141.00 from $126.00, while maintaining a Hold rating. The firm pointed to expected strength in international markets, particularly in India and the Middle East, as factors that could offset expected softness in the Americas. Additionally, Stifel reiterated a Buy rating with a $126.00 price target after meeting with ESAB’s CEO and Vice President of Investor Relations. These developments reflect ongoing strategic moves and market evaluations surrounding ESAB.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.